Do sleep peptides work? What DSIP and epitalon show
No independent controlled study found shows DSIP or epitalon improving sleep measured in a sleep lab. FDA's 2026 briefings found no evidence of effectiveness.
Peptio Research
On this page6
Neither DSIP nor epitalon, the two peptides FDA's advisory committee considered for sleep disorders in July 2026, has been shown in an independent controlled study to improve sleep measured objectively, in the sources found. For DSIP, the independent placebo-controlled polysomnography studies in people with insomnia found only weak improvements in 16 patients 1 and slow-wave sleep "not modified" in another group of people with insomnia 2. The positive reports come mainly from the group that discovered it: in 14 people with chronic insomnia it reported "substantially improved night sleep" by polysomnography, without figures in the abstract 3. For epitalon, no sleep study was found at all: its human reports measure a melatonin breakdown product in urine 4.
FDA's briefings for that meeting found no data supporting DSIP's effectiveness for chronic insomnia, narcolepsy or opioid withdrawal by the nominated route 5, and "a lack of evidence to support the effectiveness" of epitalon for insomnia 6. Both weighed against adding the substance to the 503A compounding list, and both state that FDA "will not issue a final determination" until the advisory committee process is complete 5 6.
What "works" would have to mean for sleep
Sleep can be measured directly. Polysomnography, an overnight recording of brain waves, eye movements and muscle tone, shows how long someone slept, how long they took to fall asleep and how much time they spent in each sleep stage, including slow-wave (delta) sleep, the deepest stage. Self-report, asking people how they slept, captures something real but different.
So the question for any sleep peptide is whether, in a controlled study of people with a sleep problem, polysomnography showed better sleep than placebo. A change in a hormone or its breakdown products is not a change in sleep, and neither is an EEG effect in an animal.
DSIP
DSIP, delta sleep-inducing peptide, is a chain of nine amino acids that FDA calls emideltide. The name describes how it was first characterised: in 1977, infused into the brain ventricles of rabbits, it enhanced delta and spindle patterns on the EEG 7. It is not a demonstrated effect in people. No gene, precursor protein or receptor for it has been identified, according to a 2006 review 8.
In people, the evidence is small studies from the 1980s and 1990s. Bes and colleagues recorded 16 people with chronic insomnia by polysomnography in a double-blind, placebo-controlled parallel-group study. They found higher sleep efficiency and shorter sleep latency, but called the effects "weak", said they could partly reflect a change in the placebo group, found no change in self-rated sleep quality, and concluded DSIP is "not likely to be of major therapeutic benefit" 1. Monti and colleagues, in a double-blind placebo-controlled crossover study of people with insomnia over four nights, also by polysomnography, found slow-wave sleep "not modified" and judged the improvement "of little clinical significance" 2.
The group that discovered DSIP reported better results. In 14 middle-aged people with chronic insomnia, comparing DSIP and placebo nights in the same people, they report "substantially improved night sleep" by polysomnography, with no figures in the abstract 3. The 59% figure seen online comes from their study of 6 healthy volunteers: measured by behavioural observation and EEG, sleep rose by a median of 59% over placebo in a 130-minute daytime window after a morning infusion 13. It is not a measure of night-time sleep or of insomnia.
Epitalon
Epitalon is a synthetic four-amino-acid peptide. No study of it measuring sleep, by polysomnography or by self-report, was found. In middle-aged people, a report from a Russian research group found 1.7 times higher urinary excretion of 6-sulfatoxymelatonin, a breakdown product of melatonin, with no sample size or control group in the abstract 4. A 2007 report covering epitalon and a pineal extract in old rhesus monkeys and elderly people states only that the preparations restored night-time melatonin release, without figures 15.
FDA's briefing describes the English version of the melatonin study as "a randomized, placebo-controlled study" in women aged 40 to 50 working mostly night shifts; the abstract read for this site describes neither randomisation nor a placebo, and the full text could not be opened. FDA notes that it "did not specify blinding" and states that it "did not evaluate sleep outcomes". FDA says it "did not identify studies evaluating the use of these substances in patients with insomnia" 6.
What FDA concluded
FDA's Pharmacy Compounding Advisory Committee considered emideltide on 24 July 2026 for "Opioid withdrawal, chronic insomnia, and narcolepsy", and epitalon the same day for "Insomnia". The meeting page, reopened on 6 November 2026, records no vote or outcome 16. A trade journal and a law firm, both second hand, report that the committee voted against emideltide, 6 in favour and 7 against with one abstention, and for epitalon, by what the trade journal calls a similarly tight margin, without giving a count 17 18. A vote for a substance is advice to FDA, not a finding that it works, and the epitalon vote, on these accounts, went against FDA's own briefing 17 18. HHS's October 2026 enforcement policy then named epitalon acetate, for compounders who meet ten listed conditions, and left emideltide out 19. That policy is a non-binding draft 20 and is not a finding about sleep.
For emideltide, FDA's briefing states that it "did not identify any data to support the effectiveness" for chronic insomnia, narcolepsy and opioid withdrawal by the nominated route, that there is "insufficient evidence to make a conclusion" on its effectiveness given intravenously for chronic insomnia, and that its safety "is insufficiently characterized". It concludes that the criteria weigh against placing it on the 503A list 5.
For epitalon, FDA's briefing finds "a lack of evidence to support the effectiveness" for insomnia and "no clinical data to support the safety" of either form in humans, and weighs against adding it to the list. It states that FDA "will not issue a final determination" until the advisory committee process is complete 6.
Both briefings note that FDA-approved drugs for insomnia exist 5 6. This page names none: a persistent sleep problem is a question for a clinician.
What is not known
No registered or ongoing trial of DSIP was found, and no registered human trial of epitalon. Most of the DSIP studies were read as abstracts, several do not state whether allocation was random, and none is recent. Whether either peptide changes sleep measured by polysomnography in people with insomnia, in a study large enough to tell, has not been tested in the sources found. FDA's adverse event database searches retrieved no reports for either substance, through 3 March 2024 for emideltide and through 8 December 2025 for epitalon 5 6. With so few people studied, that is not evidence of safety.
Peptides covered
Research areas
Sources
- 1. Bes F et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PubMed 1299794
- 2. Monti JM et al. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. International Journal of Clinical Pharmacology Research. 1987. PubMed 3583493
- 3. Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. European Neurology. 1987. PubMed 3622582
- 4. Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Advances in Gerontology (Uspekhi Gerontologii). 2020. PubMed 33280326
- 5. FDA Briefing Document for Emideltide-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 6. FDA Briefing Document for Epitalon-Related Bulk Drug Substances (Epitalon (free base) and Epitalon acetate), Pharmacy Compounding Advisory Committee, July 2026. U.S. Food and Drug Administration. 2026. View source(open access)
- 7. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the USA. 1977. PubMed 265572(open access)
- 8. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. PubMed 16539679
- 9. Obál F Jr et al. Effects of intracerebroventricular injection of delta sleep-inducing peptide (DSIP) and an analogue on sleep and brain temperature in rats at night. Pharmacology Biochemistry and Behavior. 1985. PubMed 3841214
- 10. Obál F Jr et al. Structure-activity relationship in the effects of delta-sleep-inducing peptide (DSIP) on rat sleep. Pharmacology Biochemistry and Behavior. 1986. PubMed 3754970
- 11. Sušić V, Masirević G, Totić S. The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat. Brain Research. 1987. PubMed 3620931
- 12. Sommerfelt L. Reduced sleep in cats after intraperitoneal injection of delta-sleep-inducing peptide (DSIP). Neuroscience Letters. 1985. PubMed 3840239
- 13. Schneider-Helmert D. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1981. PubMed 6895513
- 14. Pomfrett CJ et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. European Journal of Anaesthesiology. 2009. PubMed 19142086
- 15. Korkushko OV et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology (Uspekhi Gerontologii). 2007. PubMed 17969590
- 16. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026. View source(open access)
- 17. Steinzor P. FDA Panel Backs 6 Peptides for Compounding. AJMC (The American Journal of Managed Care). 2026. View source(open access)
- 18. Crossan SS, Watkins S. Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions. Holland & Knight Alert. 2026. View source(open access)
- 19. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B. U.S. Department of Health and Human Services. 2026. View source(open access)
- 20. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526). Federal Register. 2026. View source(open access)
- 21. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. View source(open access)